Ophthalmic laser treatments are discouraged in patients with implantable pulse generators (IPGs, pacemakers) and implantable cardioverter defibrillators (ICD) due to potential effects of the electromagnetic interference (EMI) emitted by ophthalmic laser systems. We assessed the effects of EMI generated by ophthalmic laser systems and laser discharge on IPG and ICD function.
Introduction
More than 200 000 de novo cardiac implantable electronic devices (CIEDs) are implanted in the USA each year. 1, 2 The majority of the cardiac device recipients are elderly with co-morbid conditions, who are also prone to developing ophthalmological problems such as cataract, glaucoma, and macular degeneration. Indeed, an increasing number of 193 nm excimer laser procedures such as photorefractive keratectomy (PRK) and phototherapeutic keratectomy (PTK) for therapeutic and vision correction purposes are performed on these patients, and the number of individuals with CIEDs who need to undergo ophthalmic laser procedures is increasing. 3 Ophthalmic laser systems produce electromagnetic interference (EMI) noise that could potentially disrupt the CIED's ability to operate. 4, 5 In an implantable pulse generator (IPG, pacemaker), laser burst frequencies could lead to oversensing, which may result in failure to deliver pulses when appropriate. 3, 4 In an implantable cardioverter defibrillator (ICD), EMI could trigger an inappropriate high-voltage shock, which could potentially initiate life-threatening cardiac arrhythmias. 1, 2 However, little is known about the interaction between ophthalmic laser systems and IPG and ICD function.
The ability of the CIED to accurately differentiate intrinsic signals from noise depends on device sophistication. The response to EMI is also dependent on the characteristics of the EMI, proximity to the interference, available shielding, the sensing characteristics, and programmed polarity of the device. The pacemaker circuitry is designed to attenuate any interference outside the normal intracardiac range (10-100 Hz). This is achieved by using insulated metallic shields, band pass filters, and software that can differentiate intrinsic heart signals from environmental noise. 6 -8 However, as some ophthalmic lasers, i.e. excimer lasers, are large and complex systems, their EMI and the effect on CIEDs cannot be accurately estimated. The purpose of this study was to examine whether EMI emitted by three commonly used ophthalmic lasers interfered with the function of a St Jude Medical Victory dualchamber pacemaker and Atlas II + dual-chamber ICD.
Methods
The device test fixture set-ups included two devices, TM model 1590 integrated bipolar leads were used during the testing in the ventricular port. The devices were placed in foam blocks to stabilize the leads in a position simulating the orientation and implant position as they would be in a patient. The distance between the high-voltage power supply of the laser systems and the CIEDs was ,36 in. The devices were immersed in the saline test bath. The test containers were filled with distilled water and NaCl producing a pacing impedance of 500 V. This in vitro test model is the standard method to evaluate electromagnetic compatibility for implantable pacemakers and defibrillators. 9 The Victory IPG was programmed to settings most sensitive to external signals. Atrial sensitivity was programmed to 0.1 mV (bipolar) and 0.5 mV (unipolar). The ventricular sensitivity was programmed to 0.5 mV (bipolar and unipolar). The pacing mode was set to DDI at a rate of 40 bpm (1500 ms) to allow for the longest alert period possible at maximum sensitivity, and still be able to monitor for any extraneous sensing. Atrioventricular (AV) delay was programmed to 180 ms. The electrogram (EGM) was monitored for any extraneous atrial-sensed or ventricular-sensed events. Ventricular Safety Standby was programmed to ON to ensure monitoring of the ventricular channel for any signals detected during the 'cross-talk detection window'. If any signals were detected on the ventricular channel during the cross-talk window, the AV delays would indicate as 120 ms. Episode triggers for stored EGMs were turned on for both the atrium and the ventricle. The IPG was tested both in unipolar (large antennae) and bipolar sense configurations. 10, 11 The IPG sensing settings are reported in Table 1 . The Atlas II + ICD was also programmed to settings most sensitive to external signals. Sensitivities were set to a maximum of 0.2 mV in the atrium and the ventricle. The pacing mode was set to DDI at a rate of 40 bpm (1500 ms) with a Ventricular Noise Reversion mode of DOO at 50 bpm. Atrioventricular delays were programmed to 180 ms and Ventricular Safety Standby was programmed ON. The EGM was monitored for any extraneous atrial-or ventricular-sensed event markers and noise reversions. This ICD used automatic Figure 1 ). The Threshold Start provides adjustment of the start for sensing decay allowing the device to adapt to changes in the patient's intrinsic activity. It is programmable to a percentage of the previous sensed R-wave (50 -100%) or a fixed millivolt value. The Decay Delay lengthens the period of time that the sensitivity value will be maintained at the Threshold Start value and is programmable from 0 ms (shortest) to 220 ms (longest). In this study, post-ventricular sensing settings were programmed to a Decay Delay of 0 ms (shortest) and a Threshold Start at 50% (most sensitive) with a ventricular refractory period of 125 ms (shortest). Further, post-ventricular pacing settings were programmed to a Decay Delay of 0 ms, Threshold Start at 1.0 mV, and a refractory period of 250 ms. At these post-paced settings, it will take 500 ms to reach maximum ventricular sensitivity and allow for 1000 ms at maximum sensitivity 12, 13 ( Figure 1 ). The ICD was tested with both true bipolar and integrated bipolar high-voltage ventricular leads. Its sensing settings are reported in Table 2 .
Ophthalmic lasers
The three laser systems were configured with exaggerated therapy settings ( Table 3) . For each laser system, the test chamber was oriented so that the CIED would rest in the approximate location that it would be during surgery. For example, the VISX laser and its associated laser surgeries requires that the patient be supine, whereas the Lumenis laser system requires the patient be seated upright in front of the laser. VISX Star S4: The VISX Star S4 emits a 193 nm excimer laser beam that ablates the target corneal tissue using variable beam sizes of 0.65 mm up to 6.5 mm, with the average spot size between 2.0 mm and 5.0 mm. It has a maximum beam diameter range of up to 8.0 mm and is used in laser-assisted in situ keratomileusis (LASIK), PRK, and PTK. A standard LASIK/PRK treatment requires 200-500 pulses, usually at a rate of 10 -20 Hz for 20-60 s, using a 6.5 mm beam. In this study, we used a beam of 6.5 mm blended to 8.0 mm with 500 pulses at 10 Hz for 60 s (Figure 2A) .
Lumenis Selecta II: The Lumenis Selecta II is a slit-lamp-mounted neodymium-doped yttrium aluminium garnet (Nd:YAG) laser that emits a 532 nm wavelength laser pulse. This pulse is selectively absorbed by the target tissue within the trabecular meshwork of the eye. Ultimately, this allows for aqueous humor outflow and a reduction in intraocular pressure. The procedure is called selective trabeculoplasty. Normally, surgery with this laser includes 50 -100 pulses at a power of 0.5 -1 mJ. In this study, we used 40 pulses at a power of 1 mJ for 120 s ( Figure 2B) .
Ellex Ultra Q: The Ellex Ultra Q is a Nd:YAG laser that emits a 1064 nm wavelength laser pulse. This pulse cuts through the ocular tissue for treatment of secondary cataract (posterior capsulotomy) and narrow angle glaucoma (laser iridotomy). A typical surgical procedure would use 5 pulses at 3-6 mJ on pulse train 1. We tested the devices against 10 pulses at 7 mJ on pulse train 2 ( Figure 2C ). Figure 3A and B) .
Discussion
The purpose of this in vitro study was to assess whether the St Jude Medical's Victory dual-chamber pacemaker and the Atlas II + dualchamber ICD were affected by the EMI emitted by three most commonly used ophthalmic laser systems, VISX Star S4, Lumenis Selecta II, and Ellex Ultra Q. We found that the operation of ophthalmic lasers did not lead to oversensing, inappropriate therapy, or change in the programming of the CIEDs. Potential incompatibility between ophthalmic lasers and CIEDs has been an issue for ophthalmologists for years, and warning signs are often posted outside ophthalmic laser operating rooms ( Figure 2D) . However, the precise impetus for the posting of these signs is not clear. One of the key concerns about operating on a patient with an ICD is the possibility of intra-operative highvoltage defibrillation discharge. The momentary involuntary violent movement of the patient's body due to a defibrillation shock could have deleterious consequences during ophthalmic surgery. Indeed, there are accounts of ICD discharge during non-ophthalmic surgeries, associated with electrocautery use. 14, 15 However, to our knowledge, ICD discharge during ophthalmic surgery has not been reported before. 3 The present investigation provides the first systematic evidence that an EMI-related shock does not occur with ophthalmic laser operations. Although temporary programming of the ICD to turn the high-voltage shock OFF or applying a magnet over the device are alternative options, the personnel in ophthalmic laser centres frequently lack the expertise or the necessary comfort level with CIEDs to employ these interventions. Indeed, there is a reluctance to refer patients with CIEDs for laser procedures. As such, the present data are important to reassure the patients with CIEDs and their ophthalmologists. To our knowledge, there are no published data on the compatibility of ophthalmic lasers and CIEDs. In vivo reports are limited to unpublished meeting abstracts of case reports. In one of these an ophthalmologist with an IPG (Kappa 400, Medtronic Inc.,) performed simulated LASIK and PRK surgery. Three lasers, available at that time, were used including the Summit Apex Plus (Summit Technology Inc., Walnut Creek, CA, USA), Nidek EC-5000 (Nidek Inc., Freemont, CA, USA), and VISX Star S2 Smoothscan (AMO, Santa Ana, CA, USA). Device function tests and a Holter monitor were performed post-operatively. There was one ventricular high-rate episode which did not affect device function and did not appear to be the result of EMI. The second in vivo investigation monitored a patient with ICD undergoing LASIK surgery with the VISX Star S2 Smoothscan. Extensive monitoring tools were used to assess device function intra-operatively including: real-time electrocardiogram and intra-operative EGM memory analysis. No device malfunction or oversensing occurred. However, these observations were made under usual surgical and CIED conditions. 16 The results from the present in vitro study advance these limited observations by creating 'worst-case scenario' conditions for device function, which was accomplished through two means. First, the implanted device was programmed to settings with maximum sensitivity to external signals, increasing the potential for device misinterpretation of EMI signals. Secondly, the ophthalmic laser procedure was prolonged and intensified. Maximal surgery settings, such as the widest excimer laser beam diameter was used for a longer duration than most surgeries to ensure that the devices are tested against worse conditions than a patient would ever experience. Of note, these results are consistent with a previous report by Sher et al. 17 where two Medtronic devices were tested in vitro using a similar design. Ophthalmic laser EMI primarily comes from the design of the hardware electro mechanics, laser conversion, and laser application. Each laser system differs with regard to equipment design, delivered energy, and available therapies. During ophthalmic laser irradiation of ocular tissue, the amount of laser energy reflected or absorbed is based on multiple variables. These include the wavelength and pulse characteristics of the laser used and the target ocular tissue. In photocoagulation of the retina using an argon laser, almost all the laser energy passes through the cornea and crystalline lens and is absorbed by the pigmented portions of the choroids. 18 In excimer laser surgery of the cornea, almost all of the 193 nm energy is absorbed by the cornea that is ablated. 19 Because the laser's coherent radiation is locally absorbed and attenuated by the surrounding tissue, the ablation process might not be considered a significant source of interference for the CIEDs. The systematic approach utilized in the examination of the CIEDs and the creation of vigorous testing conditions are the strengths of this investigation. On the other hand, some limitations are also worth noting. First, the study was limited to St Jude Medical Victory IPG and Atlas II + ICD implantable devices and the VISX Excimer Star S4, Lumenis Selecta II, and the Ellex Ultra Q laser systems. Although there are industry standards and regulations that must be met by all ICDs and IPGs, each model possesses unique design properties. Thus, CIEDs or lasers that were not examined in this study should be subjected to similar investigations. Secondly, the study was in vitro. Although the in vitro nature of the study allowed us to employ most sensitive settings, in vivo examinations in patients would be complementary to our data.
In conclusion, EMI emitted from widely used ophthalmic lasers VISX Star S4, Lumenis Selecta II, and Ellex Ultra Q does not lead to oversensing, inappropriate therapy, or change in the programming of the St Jude Medical Victory dual-chamber pacemaker and the Atlas II + dual-chamber ICD.
